FLT3 and acute myeloid leukemia: SEL24-B489 (MEN1793; Figure 4) is a dual-type I PIM/FLT3 inhibitor based on the benzoimidazole scaffold showing broad activity in AML cell lines and primary AML blasts and efficacy on AML xenografts [58]; SEL24-B489 entered Phase I/II clinical trials on AML in 2017 (NCT03008187).